BioMark Diagnostics, Inc. · CSE:BUX

BioMark Diagnostics — Investor Presentation (June 2016)

23 slides from BioMark Diagnostics's investor presentation, June 2016

  1. Slide 1: BioMark Diagnostics Inc: A Next Generation Company Powered by Metabolomics

    Slide 1: BioMark Diagnostics Inc: A Next Generation Company Powered by Metabolomics

    BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics June 2016 OTC: BMKDF CSE: BUX www.biomarkdiagnostics.com BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics 1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements or projections contained in this presentation are forward-looking statements, including those that discuss strategies, goals, outlook or other non-historical matters; or project revenues, income, product development, regulatory approval, returns or other

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    Company Overview Why We Are •To provide universal access to cancer detection through a new paradigm in cancer diagnostics using metabolomics Who We Are -Oncology-focused company with advanced near-to-market diagnostic technologies -Core IP exclusively licensed from the University of Manitoba in Cana

  4. Slide 4: Executive Team

    Slide 4: Executive Team

    Executive Team Rashid Ahmed – Founder, Chief Executive Officer Dr. Thomas Malcolm – President & Chief Scientific Officer USA Dr. Bram Ramjiawan – Clinical Trial and Regulatory Expertise Brian Cheng – Chief Technical Officer Abbey Abdiye – Chief Financial Officer Dr. Kenneth Kohn – Patent Attorney US

  5. Slide 5: Scientific and Supporting Board

    Slide 5: Scientific and Supporting Board

    Scientific and Supporting Board Research / Scientific / Clinical Dr. Daniel S. Sitar Principal Scientific Advisor/Consultant Dr. John Yoo Clinical Oncologist - Co-Chair CancerCare Ontario Head and Neck; Professor, Dept. of Oncology, Schulich School of Medicine & Dentistry, Western Ontario Dr. John S

  6. Slide 6: Investment Highlights

    Slide 6: Investment Highlights

    Investment Highlights • Addressing global next-generation cancer diagnostics market expected to reach $10 billion by 2019 - Growth fueled by new cancer therapeutics, monitoring and companion diagnostics – era of personalized medicine • Rapid growth in retail health spurring need for better diagnosti

  7. Slide 7: Investment Highlights

    Slide 7: Investment Highlights

    Investment Highlights • Lead technology features non-invasive approach with high specificity and sensitivity • Planned submission for Health Canada in 2Q/Q3 2016 – approval expected in 6-9 months pending results; FDA submission to follow • Potential to generate multiple revenue streams from product

  8. Slide 8: Global Cancer Diagnostics Market

    Slide 8: Global Cancer Diagnostics Market

    Global Cancer Diagnostics Market Next-Generation Cancer Diagnostic Size of Next-Generation* Cancer Diagnostic Market Growth Projections to Total Diagnostic Market, 2014 - 2019 12 10 U.S. Dollars in Billions $157.5 $117.6 Billion Billion 8 $1.8 B $10 B 40% 6 CAGR 10 B 2014 2019 4 2 *Genetic screening

  9. Slide 9: Current Cancer Detection Methods

    Slide 9: Current Cancer Detection Methods

    Current Cancer Detection Methods • Imaging • CT ( Computed Tomography) • Mammograms • MRI • Fluorescent Challenge: There is limit to its sensitivity, as tumors that are less than 1 cm can be detected only on rare occasions • Endoscopy – Typically detected late • Cell Morphology – biopsy or cytology

  10. Slide 10: BioMark - New Paradigm in Cancer Diagnostics

    Slide 10: BioMark - New Paradigm in Cancer Diagnostics

    BioMark - New Paradigm in Cancer Diagnostics Portfolio of Cancer Diagnostic Technologies based on Metabolites • Detection of over-expression of an enzyme SSAT1* • Subject ingests FDA-approved drug amantadine which is converted into acetylated form • Detecting by-product of SSAT1 reaction - safe, sta

  11. Slide 11: BioMark Advantage – early and better detection

    Slide 11: BioMark Advantage – early and better detection

    BioMark Advantage – early and better detection BioMark Metabolite Traditional Biomarkers Approach Detection through Limited levels of biomarkers accumulated by-product of create detection challenges enzyme reaction Levels of detection many Typically limited to times better than traditional detection

  12. Slide 12: Methods of Amantadine Detection

    Slide 12: Methods of Amantadine Detection

    Methods of Amantadine Detection – Developed and owned by BioMark LC/MS – Gold Standard •Highly sensitive detection from urine •Secured Investigational and Testing Authorization from Health Canada 2014 ELISA Kit – Project started with Kestrel; Prototype expected in 6-9 months post trial results •Accu

  13. Slide 13: Methods of Amantadine Detection: IVD Kit and SERS

    Slide 13: Methods of Amantadine Detection: IVD Kit and SERS

    Methods of Amantadine Detection – Developed and owned by BioMark IVD Kit • Home antibody test for detection in urine • Use by cancer survivors for monitoring or cancer-free progression status Surface-enhanced Raman Spectroscopy (SERS) • Highly accurate photonic approach using urine • Compact, simple

  14. Slide 14: Metabolite Fingerprint Diagnostic Assays

    Slide 14: Metabolite Fingerprint Diagnostic Assays

    Metabolite Fingerprint Diagnostic Assays - In Development and Revalidation Stage  Resolving metabolite fingerprints for lung cancer in various stages - Measure levels of various empirically chosen metabolites in urine associated with lung cancer - Non-invasive - Metabolites measured using LC/MS and

  15. Slide 15: BioMark's Clinical Utility

    Slide 15: BioMark's Clinical Utility

    BioMark’s Clinical Utility BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics 15

  16. Slide 16: Target Market Focus

    Slide 16: Target Market Focus

    Target Market Focus Market Potential Market Focus Lung Cancer Diagnostic Global - $1.2 Billion Lung Cancer: Response to Treatment – Surgical and Chemo 15 million cancer survivors in Red alert monitoring for North America cancer recurrence Low cost screening tool for > 2 billion patients globally hig

  17. Slide 17: Product Development Pipeline

    Slide 17: Product Development Pipeline

    Product Development Pipeline Up to 6 months U.S. Planning Development Validation Market Approval Internal standards developed and data SSAT-Amantadine Assay using LC/MS points collected and to be validated. Transferable to FDA SSAT-Amantadine Assay using ELISA Kit In collaboration with Kestrel Scien

  18. Slide 18: Regulatory Trials Planned Timelines – Health Canada and FDA

    Slide 18: Regulatory Trials Planned Timelines – Health Canada and FDA

    Regulatory Trials Planned Timelines – Health Canada and FDA Trials Expected Timing 220 Patient Trial Completed Internal Standards developed Data Readout and Analysis Health Canada Submission 3Q16 Health Canada Approval Decision 2016/17 FDA Submission/Approval 2H17 Response to Treatment - Chemotherap

  19. Slide 19: Competitive Landscape

    Slide 19: Competitive Landscape

    Competitive Landscape Company Biomarker Cancer Diagnostic Pre-Visible Pre- Development Tumor Symptomatic Stage Detection Tumors Broad coverage BioMark Lung Cancer N-acetylamantadine YES YES Diagnostics Near to Market Lung, breast, prostate Broad coverage Prostate, GI, stromal, Cellmid Ltd. Midkine N

  20. Slide 20: Potential Revenue Streams

    Slide 20: Potential Revenue Streams

    Potential Revenue Streams Sales of products / supplies (kits and internal standards) Royalty on lab analysis (per test) Licensing – Territorial and distribution licensing Services • Monitoring • CDx for drug companies (Surrogate Biomarker) BioMark DIAGNOSTICS INC A Next Generation Company Powere

  21. Slide 21: Share Structure

    Slide 21: Share Structure

    Share Structure • Share Summary LISTING: - Shares: 53,345,776 / Tradable Share: 23,345,776 - CSE: BUX CANADA - Warrants: 1,363,181 - OTCQB: BMKDF U.S.A - FSE: 20B GERMANY • Private Placement • November 2014: at 25 cents, raised $ 530,000, no warrants. • February 2015: at 50 cents, raised $ 750,000,

  22. Slide 22: Proposed Use of Proceeds

    Slide 22: Proposed Use of Proceeds

    Proposed Use of Proceeds ‣ Complete protocol development, submissions to Health Canada and commence studies for to lung cancer chemo and resection studies ‣ Assay optimization and re-validation and Kit development for lung cancer fingerprints (TMIC) ‣ Patent fillings and support ‣ Data Compilation a

  23. Slide 23: Investment Highlights

    Slide 23: Investment Highlights

    Investment Highlights • Addressing global next-generation cancer diagnostics market expected to reach $10 billion by 2019 • Launching new paradigm for early cancer detection based on metabolites with potential to become new standard of care • Cost reduction in medical care or improved productivity •

Source: Internet Archive copy of biomarkdiagnostics.com

More decks from BioMark Diagnostics, Inc.

All 7 BioMark Diagnostics decks